AGMB AgomAb Therapeutics NV
$13.06▼ -6.31%
Healthcare
Other
After hours
$12.81▼ -1.91%
Sep 11, 7:30 PM ET
Volume 196.7K
Avg Volume (10D) 200.6K
Key Metrics & Fundamentals
Market Cap
$643.18M
P/E Ratio
–
Div Yield
–%
52W Range
8.75 - 17.82
% vs 50 MA
-2.38%
% vs 200 MA
–%
RSI-14
44.7
MACD Histogram
-0.0500
Beta (1Y vs SPY)
2.03
Free Cash Flow
-$13.18M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$17.62M
COGS
–
Operating Exp
$16.53M
Operating Income
-$16.53M
EBIT
-$16.53M
Pretax Income
-$17.40M
Net Income
-$17.40M
Price & Volume History
Loading chart…
Recent News
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
GlobeNewswire · Sep 11, 2026 8:05 PM
Agomab to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 8:05 PM
Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight
MT Newswires · Aug 19, 2026 10:47 AM
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
GlobeNewswire · Aug 10, 2026 8:07 PM
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
GlobeNewswire · Aug 6, 2026 8:01 PM
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target
MT Newswires · Jul 23, 2026 12:22 PM
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
Insider Monkey · Jul 2, 2026 8:06 PM
European Equities Traded in the US as American Depositary Receipts Decline Friday
MT Newswires · Jun 26, 2026 3:06 PM
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease
MT Newswires · Jun 23, 2026 9:32 PM
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
GlobeNewswire · Jun 23, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AGMB's money flow as a full page
Social Sentiment
No Reddit posts found for AGMB.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.